Research ResourceDRUG DEVELOPMENT

Hyperactive locomotion in a Drosophila model is a functional readout for the synaptic abnormalities underlying fragile X syndrome

See allHide authors and affiliations

Sci. Signal.  02 May 2017:
Vol. 10, Issue 477, eaai8133
DOI: 10.1126/scisignal.aai8133

You are currently viewing the editor's summary.

View Full Text

Log in to view the full text

Log in through your institution

Log in through your institution

Spurring drug development for FXS

Fragile X syndrome (FXS) is an autistic intellectual disability disorder caused by loss of the RNA binding protein FMRP. Treating FXS has been challenging because of the lack of a reliable in vivo drug screening model. Kashima et al. found that the hyperactive locomotion observed in a fly model of FXS was a reliable behavioral marker for the neurological abnormalities underlying the disease. The kinase LIMK1 is implicated in the pathogenesis of FXS, and high-throughput (rapid, quantitative, and time- and cost-effective) drug screening in the fly FXS model confirmed that LIMK1 inhibitors ameliorated both the neurological and behavioral phenotypes of this model. LIMK1 inhibitors also reduced hyperactivity in a mouse model of FXS. Thus, this method may aid in future drug development for FXS patients.